Clinical trials located in


Uppsala city is located in Sweden. Currently, 20 clinical trials are being conducted in this city.

Uppsala, Sweden’s fourth-largest city, is steeped in rich history and academic prestige. Founded in the 5th century, it is home to Scandinavia’s oldest university, Uppsala University, established in 1477. The city is also known for its remarkable Uppsala Cathedral, the tallest church in Scandinavia, dating back to the 13th century. Uppsala was once the religious center of Sweden, and its ancient pagan site, Gamla Uppsala, features royal burial mounds from the 6th century. The city seamlessly blends its historical legacy with vibrant modern life.

  • CT-EU-00121567

    Study of Giredestrant and other drugs in patients with HER2-negative early breast cancer

    This study focuses on early stage breast cancer with estrogen receptor (ER)-positive and HER2-negative status. The study compares the effectiveness and safety of giredestrant with the physician’s choice of endocrine (hormonal) therapy.

    The study involves participants with histologically confirmed (histology is the study of tissues) early stage breast cancer in stages I to III, who are at medium to high risk. Patients must have had their primary breast tumor and axillary lymph nodes surgically removed.

    The aim is to evaluate how well giredestrant works compared to the standard hormonal therapy chosen by the physician in preventing the recurrence of cancer after treatment for early stage breast cancer. Giredestrant is administered orally once daily for 5 years.

    Both men and women may qualify for the study, provided they meet certain health and surgical criteria. This study also includes an additional substudy to explore the safety of combining giredestrant with abemaciclib in a selected group of participants.

    Giredestrant acts as an antagonist (blocking agent) to estrogen receptors, aiming to reduce the risk of cancer recurrence. Abemaciclib is an oral medication that inhibits the enzyme called cyclin-dependent kinase 4/6 (CDK4/6), which helps to stop the growth of cancer cells.

    The ultimate goal of the study is to determine whether giredestrant or its combination with abemaciclib can offer better treatment outcomes than the currently used hormonal therapies in preventing breast cancer recurrences.

    • Endocrine Therapy of Physician’s Choice
    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    • Belzutifan
  • Comparison of different drug combinations in the treatment of relapsed mantle cell lymphoma

    In this trial, Glofitamab will be tested on patients with mantle cell lymphoma that has either recurred or not responded to prior therapy. The effectiveness of this medicine will be compared to alternative treatments suggested by physicians, such as a rituximab and bendamustine mix or a combination of lenalidomide and rituximab. Participants will be asked questions about their physical and emotional well-being, ability to handle day-to-day responsibilities, cognitive function, social lifestyle, symptoms like tiredness, vomiting, pain, etc., and overall health condition and life quality.

    • Tocilizumab
    • Obinutuzumab
    • Glofitamab
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Investigating safety and effects of new medicine in overweight diabetic patients

    This trial is exploring AZD9550, a new drug in development for treating non-alcoholic steatohepatitis (NASH), a liver disease often seen in overweight or obese individuals with type 2 diabetes mellitus (T2DM). The study will involve 88 participants aged 18 to 65 who are overweight or obese and living with T2DM. The study is divided into four parts, with varying doses of AZD9550 administered subcutaneously (under the skin) to evaluate its safety, how well it is tolerated, and how it affects the body. The trial will also compare the effects of AZD9550 to a placebo (a substance with no therapeutic effect) to benchmark its safety and tolerability.

    • AZD9550- new medication for non-alcoholic steatohepatitis and metabolic dysfunction-associated steatohepatitis
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    • Sotatercept
  • Studying riliprubart’s effect on the prevention and treatment of antibody-mediated rejection

    The aim of this study is to test a new drug called Riliprubart (BIVV020) to see if it can help address a common problem in kidney transplant patients called antibody-mediated rejection (AMR). AMR happens when the body fights against the new kidney. The study consists of two parts: group one tests whether Riliprubart can prevent the development of antimicrobial resistance, while group B tests whether it can help if antimicrobial resistance already exists. The test also checks whether the drug is safe, how it works in the body and whether the body perceives it as something foreign. The study lasts about 2 years, during which doctors carefully monitor the condition of the patients’ kidneys, possible side effects and how the drug moves through the body after administration.

    • Riliprubart
    • Immunoglobulin (IVIg)
    • Antithymocyte globulin
    • Mycophenolate
    • Rituximab
    • Corticosteroids
    • Tacrolimus
  • Comparing favezelimab/pembrolizumab combo with standard chemotherapy for Hodgkin lymphoma

    This study is investigating a treatment for PD-(L)1-refractory, relapsed, or refractory classical Hodgkin lymphoma, a type of blood cancer. Researchers are evaluating a new drug combination known as MK-4280A (favezelimab/pembrolizumab) alongside standard drugs typically used for this condition (bendamustine or gemcitabine). The aim is to determine if MK-4280A is superior to the standard drugs in extending patients’ lifespan and slowing down disease progression. Additionally, scientists will assess the safety and tolerability of MK-4280A during the study, noting any potential side effects of the drug.

    • Favezelimab
    • Pembrolizumab
    • Bendamustine
    • Gemcitabine
  • Testing personalized treatments for advanced prostate cancer

    ProBio is a worldwide study for patients with advanced prostate cancer. It will look at whether new treatments can help patients based on their unique cancer characteristics. Patients are allocated in two groups: one will receive usual care following local guidelines (control group). The other group will be given treatments designed specifically for their type of cancer. These treatments will be chosen based on their cancer’s unique characteristics – what is called ‘biomarker signatures’. Depending on how well they respond to the treatment, patients may be moved to different treatments. Each treatment will be compared to standard care for effectiveness. The researchers will decide if treatments are effective, should continue, or should be stopped. New types and combinations of treatments can be included in the future. The study will use well-established standards to assess cancer improvement. Quality of life and costs of the treatment will also be evaluated. Side effects and responses to treatment at 6 months will also be recorded.

    • Abiraterone
    • Cabazitaxel
    • Radium Chloride Ra-223
    • enzalutamide
    • Apalutamide
    • Niraparib
    • Darolutamide
    • Capivasertib
    • Prednisone
    • Carboplatin
    • Docetaxel
  • Comparing Imlifidase with standard treatment in anti-glomerular basement membrane disease

    This clinical trial is testing a medication called Imlifidase in patients who have a serious disease called anti-GBM (Goodpasture syndrome). The researchers are doing this study to compare two groups: people who take Imlifidase along with the usual treatment, and people who only get the usual treatment. This typical treatment consists of plasma exchange (PLEX), Cyclophosphamide and glucocorticoids. This study will last for 2 years. Researchers will measure things like kidney function, levels of harmful anti-GBM antibodies, breathing symptoms, drug interaction and patients’ quality of life.

    • Cyclophosphamide (CYC)
    • Glucocorticoids
    • Imlifidase
  • Studying rimegepant’s effectiveness on Migraine

    This study is testing a new treatment, rimegepant, for adults with migraines who cannot take traditional migraine medications, such as triptans, possibly due to reasons like having a heart condition. The research aims to evaluate the effectiveness and tolerability of rimegepant over a 12-week period. Participants will be asked to rate their headache pain on a scale ranging from 0 (no pain) to 3 (severe pain) as one of the methods to assess the treatment’s impact.

    • Rimegepant
  • Study on treating uncontrolled bleeding with bentracimab

    A trial investigating bentracimab’s ability to reverse ticagrelor’s effects in patients with severe bleeding or those needing urgent surgery. The study, involving at least 200 patients from various regions, tests if bentracimab can quickly counteract ticagrelor, improving patients’ conditions or allowing for safe surgeries. Patients receive a thorough follow-up to ensure the drug’s effectiveness and safety, aiming to provide a reliable treatment for critical, time-sensitive medical scenarios.

    • bentracimab/PB2452
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Examining the efficacy of Imlifidase in kidney transplant patients

    This study will test the drug imlifidase on patients who require a kidney transplant but have a condition that makes their body reject the new organ. In this study, the goal is to assess the effectiveness of imlifidase in facilitating acceptance of new organs among patients and evaluating the kidney’s functionality one year post-transplant. The patients, who must consent after being made aware of the risks, will be compared to two groups — one group who has recently received a transplant and another historical group from records of transplants. Imlifidase works by removing harmful antibodies quickly, allowing the body to accept the new organ. But after the transplant, these antibodies can come back. Therefore, patients in this study will be closely watched for any signs of their body rejecting the new organ, like through blood tests and organ checks at 6 months and 1 year.

    • Imlifidase
  • Comparison of new treatment and standard care for lymphoma patients

    A new approach to treating Lymphoma, a type of cancer originating in cells constituting the body’s immune system, is being tested in this trial. Comparison is being made between a new treatment, referred to as MB-CART2019.1, and the presently conventional treatment. The MB-CART2019.1 therapy is designed to target the aberrant B cells responsible for this form of cancer. In the process of creating MB-CART2019.1, cells are extracted from the patient’s own body, modified in the laboratory to combat cancer, and subsequently reintroduced into the patient. Participants in this trial will receive either MB-CART2019.1 or the standard treatment. The standard treatment involves the use of a drug combination (rituximab, gemcitabine, oxaliplatin (R-GemOx) or bendamustine, rituximab (BR) + polatuzumab vedotin). The objective is to assess whether MB-CART2019.1 demonstrates superior efficacy compared to these conventional drugs. Patient progress will be closely monitored for approximately one year to evaluate their well-being.

    • Gemcitabine
    • Polatuzumab vedotin
    • Bendamustine
    • Rituximab
    • Oxaliplatin
    • Rituximab
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    • Carfilzomib
    • Pomalidomide
    • Teclistamab
    • Dexamethasone
    • Bortezomib

See more clinical trials in other cities in Sweden: